share_log

SC 13G: Statement of acquisition of beneficial ownership by individuals-Sir Marc Feldmann(8.6%)

SC 13G: Statement of acquisition of beneficial ownership by individuals-Sir Marc Feldmann(8.6%)

SC 13G:超過5%持股股東披露文件-Sir Marc Feldmann(8.6%)
美股SEC公告 ·  10/19 05:04

牛牛AI助理已提取核心訊息

On September 5, 2024, Sir Marc Feldmann filed a Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in 180 Life Sciences Corp. The filing revealed that Feldmann holds 90,532 shares of the company's common stock, which includes options to purchase an additional 20,000 shares. As of the filing date, this represented 8.6% of the company's class of securities. However, by October 17, 2024, his percentage ownership decreased to 4.5%. The filing was made in accordance with Rule 13d-1(b) and Rule 13d-1(c), and Feldmann certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer. Sir Marc Feldmann, a UK and Australian citizen, is known for his contributions to the field of immunology and has a principal business address in London, UK.
On September 5, 2024, Sir Marc Feldmann filed a Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant ownership stake in 180 Life Sciences Corp. The filing revealed that Feldmann holds 90,532 shares of the company's common stock, which includes options to purchase an additional 20,000 shares. As of the filing date, this represented 8.6% of the company's class of securities. However, by October 17, 2024, his percentage ownership decreased to 4.5%. The filing was made in accordance with Rule 13d-1(b) and Rule 13d-1(c), and Feldmann certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer. Sir Marc Feldmann, a UK and Australian citizen, is known for his contributions to the field of immunology and has a principal business address in London, UK.
2024年9月5日,馬克·費爾德曼爵士向美國證券交易委員會(SEC)提交了13G表,表示對180 Life Sciences Corp.擁有重要股權。申報顯示,費爾德曼持有該公司普通股的90,532股,其中包括購買額外20,000股股票的期權。截至申報日,這佔公司證券種類的8.6%。然而,到2024年10月17日,他的持股比例降至4.5%。此申報符合13d-1(b)條和13d-1(c)條規定,費爾德曼證實這些股份並非是爲了改變或影響發行人的控制權。馬克·費爾德曼爵士是英國和澳大利亞公民,以其對免疫學領域的貢獻而聞名,並在英國倫敦擁有主要業務地址。
2024年9月5日,馬克·費爾德曼爵士向美國證券交易委員會(SEC)提交了13G表,表示對180 Life Sciences Corp.擁有重要股權。申報顯示,費爾德曼持有該公司普通股的90,532股,其中包括購買額外20,000股股票的期權。截至申報日,這佔公司證券種類的8.6%。然而,到2024年10月17日,他的持股比例降至4.5%。此申報符合13d-1(b)條和13d-1(c)條規定,費爾德曼證實這些股份並非是爲了改變或影響發行人的控制權。馬克·費爾德曼爵士是英國和澳大利亞公民,以其對免疫學領域的貢獻而聞名,並在英國倫敦擁有主要業務地址。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。